🚀 VC round data is live in beta, check it out!
Indivior Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for Indivior Pharmaceuticals and similar public comparables like Livzon Pharmaceutical Group, Hualan Biological Engineering, Zealand Pharma, Ajanta Pharma and more.
Indivior Pharmaceuticals Overview
About Indivior Pharmaceuticals
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease.
Founded
2014
HQ
Employees
1.1K
Website
Sectors
Financials (LTM)
EV
$4B
Indivior Pharmaceuticals Financials
Indivior Pharmaceuticals reported last 12-month revenue of $1B and EBITDA of $458M.
In the same LTM period, Indivior Pharmaceuticals generated $1B in gross profit, $458M in EBITDA, and $339M in net income.
Revenue (LTM)
Indivior Pharmaceuticals P&L
In the most recent fiscal year, Indivior Pharmaceuticals reported revenue of $1B and EBITDA of $428M.
Indivior Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $1B | XXX | $1B | XXX | XXX | XXX |
| Gross Profit | $1B | XXX | $993M | XXX | XXX | XXX |
| Gross Margin | 83% | XXX | 80% | XXX | XXX | XXX |
| EBITDA | $458M | XXX | $428M | XXX | XXX | XXX |
| EBITDA Margin | 38% | XXX | 35% | XXX | XXX | XXX |
| EBIT Margin | 27% | XXX | 21% | XXX | XXX | XXX |
| Net Profit | $339M | XXX | $320M | XXX | XXX | XXX |
| Net Margin | 28% | XXX | 26% | XXX | XXX | XXX |
| Net Debt | — | — | $124M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Indivior Pharmaceuticals Stock Performance
Indivior Pharmaceuticals has current market cap of $4B, and enterprise value of $4B.
Market Cap Evolution
Indivior Pharmaceuticals' stock price is $32.16.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4B | $4B | 0.0% | XXX | XXX | XXX | $2.56 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialIndivior Pharmaceuticals Valuation Multiples
Indivior Pharmaceuticals trades at 3.2x EV/Revenue multiple, and 8.6x EV/EBITDA.
EV / Revenue (LTM)
Indivior Pharmaceuticals Financial Valuation Multiples
As of March 29, 2026, Indivior Pharmaceuticals has market cap of $4B and EV of $4B.
Equity research analysts estimate Indivior Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Indivior Pharmaceuticals has a P/E ratio of 11.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV/Revenue | 3.2x | XXX | 3.2x | XXX | XXX | XXX |
| EV/EBITDA | 8.6x | XXX | 9.2x | XXX | XXX | XXX |
| EV/EBIT | 12.0x | XXX | 14.8x | XXX | XXX | XXX |
| EV/Gross Profit | 3.9x | XXX | 4.0x | XXX | XXX | XXX |
| P/E | 11.9x | XXX | 12.6x | XXX | XXX | XXX |
| EV/FCF | 269.3x | XXX | (42.7x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Indivior Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Indivior Pharmaceuticals Margins & Growth Rates
Indivior Pharmaceuticals' revenue in the last 12 month declined by (4%).
Indivior Pharmaceuticals' revenue per employee in the last FY averaged $1.2M.
Indivior Pharmaceuticals' rule of 40 is 34% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Indivior Pharmaceuticals' rule of X is 28% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Indivior Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (4%) | XXX | (6%) | XXX | XXX | XXX |
| EBITDA Margin | 38% | XXX | 35% | XXX | XXX | XXX |
| EBITDA Growth | 23% | XXX | 29% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 34% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 28% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 25% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 26% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 7% | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 59% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Indivior Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Livzon Pharmaceutical Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Hualan Biological Engineering | XXX | XXX | XXX | XXX | XXX | XXX |
| Zealand Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Ajanta Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Ipca Laboratories | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Indivior Pharmaceuticals M&A Activity
Indivior Pharmaceuticals acquired XXX companies to date.
Last acquisition by Indivior Pharmaceuticals was on XXXXXXXX, XXXXX. Indivior Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Indivior Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialIndivior Pharmaceuticals Investment Activity
Indivior Pharmaceuticals invested in XXX companies to date.
Indivior Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Indivior Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Indivior Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Indivior Pharmaceuticals
| When was Indivior Pharmaceuticals founded? | Indivior Pharmaceuticals was founded in 2014. |
| Where is Indivior Pharmaceuticals headquartered? | Indivior Pharmaceuticals is headquartered in United States. |
| How many employees does Indivior Pharmaceuticals have? | As of today, Indivior Pharmaceuticals has over 1K employees. |
| Is Indivior Pharmaceuticals publicly listed? | Yes, Indivior Pharmaceuticals is a public company listed on Nasdaq. |
| What is the stock symbol of Indivior Pharmaceuticals? | Indivior Pharmaceuticals trades under INDV ticker. |
| When did Indivior Pharmaceuticals go public? | Indivior Pharmaceuticals went public in 2014. |
| Who are competitors of Indivior Pharmaceuticals? | Indivior Pharmaceuticals main competitors are Livzon Pharmaceutical Group, Hualan Biological Engineering, Zealand Pharma, Ajanta Pharma. |
| What is the current market cap of Indivior Pharmaceuticals? | Indivior Pharmaceuticals' current market cap is $4B. |
| What is the current revenue of Indivior Pharmaceuticals? | Indivior Pharmaceuticals' last 12 months revenue is $1B. |
| What is the current revenue growth of Indivior Pharmaceuticals? | Indivior Pharmaceuticals revenue growth (NTM/LTM) is (4%). |
| What is the current EV/Revenue multiple of Indivior Pharmaceuticals? | Current revenue multiple of Indivior Pharmaceuticals is 3.2x. |
| Is Indivior Pharmaceuticals profitable? | Yes, Indivior Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Indivior Pharmaceuticals? | Indivior Pharmaceuticals' last 12 months EBITDA is $458M. |
| What is Indivior Pharmaceuticals' EBITDA margin? | Indivior Pharmaceuticals' last 12 months EBITDA margin is 38%. |
| What is the current EV/EBITDA multiple of Indivior Pharmaceuticals? | Current EBITDA multiple of Indivior Pharmaceuticals is 8.6x. |
| What is the current FCF of Indivior Pharmaceuticals? | Indivior Pharmaceuticals' last 12 months FCF is $15M. |
| What is Indivior Pharmaceuticals' FCF margin? | Indivior Pharmaceuticals' last 12 months FCF margin is 1%. |
| What is the current EV/FCF multiple of Indivior Pharmaceuticals? | Current FCF multiple of Indivior Pharmaceuticals is 269.3x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.